Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	85.77M 8.82M 7.72M 7.13M 6.66M 12.53M 834M 12.81M 33.11M 411M 33.11M 32.39M 1.43B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	85.77M 8.82M 7.72M 7.13M 6.66M 12.53M 834M 12.81M 33.11M 411M 33.11M 32.39M 1.43B	EV / Sales 2026 *	1.13x	EV / Sales 2027 *	-
Free-Float	23.86%	Yield 2026 *	-	Yield 2027 *	-

06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW
06-09	Calendar Wednesday June 10	FW
05-21	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
05-11	Annexin receives German approval for ANXV clinical trial	RE
05-11	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study	CI
04-23	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Annexin Pharmaceuticals AB Provides Update on ANXV Clinical Study in Retinal Vein Occlusion and Diabetic Retinopathy	CI
04-13	Annexin Pharmaceuticals Mulls SEK20 Million Rights Issue; Bridge Facility Secured	MT
04-13	Annexin secures financing through bridge loan facility, plans rights issue	RE
03-26	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
02-05	Annexin Pharmaceuticals Q4 net loss at SEK 10.5 mln	RE

06-23	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO	AQ
06-15	The subscription period in Annexin Pharmaceuticals’ rights issue begins today	AQ
06-10	Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue	AQ
06-05	Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10	AQ
06-03	Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million	AQ

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	2018-12-31
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	2015-12-31
Susanne Andersson DFI	Director of Finance/CFO	55	2023-04-10

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	2016-12-31
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	2023-12-31

Annexin Pharmaceuticals AB (publ) Stock Nasdaq Stockholm

Stocks

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB (publ)

Latest news : Annexin Pharmaceuticals AB (publ)

Press Releases: Annexin Pharmaceuticals AB (publ)

News in other languages: Annexin Pharmaceuticals AB (publ)

Quotes and Performance

Managers and Directors: Annexin Pharmaceuticals AB (publ)

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB (PUBL)	+7.35%	-16.43%	-	-	9.12M
ARGENX SE	+0.13%	+1.50%	+63.86%	+123.95%	55.63B
WUXI APPTEC CO., LTD.	+6.76%	+22.83%	+91.66%	+101.42%	52.25B
BIONTECH SE	+0.62%	+4.51%	-11.47%	-11.91%	23.07B
INSMED INCORPORATED	+0.24%	+6.34%	+4.19%	+416.02%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	+6.78%	+14.47%	+40.28%	-6.67%	17.32B
GENMAB A/S	+0.97%	+5.01%	+31.23%	-32.10%	15.94B
EXELIXIS, INC.	+0.97%	+5.58%	+23.01%	+185.94%	13.77B
PHARMAESSENTIA CORPORATION	+9.96%	+19.81%	+157.65%	+320.70%	13.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.21%	+4.76%	+33.21%	-	12.43B
Average	+3.99%	+6.84%	+48.18%	+137.17%	25.14B
Weighted average by Cap.	+3.42%	+7.62%	+54.00%	+128.56%

	2026 *	2027 *
Net sales	75.6M 7.77M 6.81M 6.28M 5.87M 11.04M 735M 11.29M 29.19M 362M 29.19M 28.55M 1.26B	-
Net income	19.6M 2.01M 1.76M 1.63M 1.52M 2.86M 191M 2.93M 7.57M 93.98M 7.57M 7.4M 326M	-58M -5.96M -5.22M -4.82M -4.5M -8.47M -564M -8.67M -22.39M -278M -22.39M -21.9M -966M
Net Debt	-	-